115 related articles for article (PubMed ID: 31238062)
1. Comparative transcriptome analysis of peripheral blood mononuclear cells in renal transplant recipients in everolimus- and tacrolimus-based immunosuppressive therapy.
Granata S; Santoro G; Signorini L; Malerba G; Patuzzo C; Gambaro G; Stallone G; Zaza G
Eur J Pharmacol; 2019 Sep; 859():172494. PubMed ID: 31238062
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
3. Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen.
Zaza G; Dalla Gassa A; Felis G; Granata S; Torriani S; Lupo A
PLoS One; 2017; 12(5):e0178228. PubMed ID: 28542523
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients.
Lemaitre F; Antignac M; Fernandez C
Clin Biochem; 2013 Oct; 46(15):1538-41. PubMed ID: 23454394
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic Drug-Drug Interaction on Human Peripheral Blood Mononuclear Cells Between Everolimus and Tacrolimus at the Therapeutic Concentration Range in Renal Transplantation.
Okihara M; Takeuchi H; Akiyama S; Yoshinaga R; Osato S; Akashi I; Kihara Y; Konno O; Iwamoto H; Oda T; Tanaka S; Unezaki S; Hirano T
Ann Transplant; 2021 Feb; 26():e928817. PubMed ID: 33633104
[TBL] [Abstract][Full Text] [Related]
6. Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation.
Mathew JM; Kurian S; Cravedi P; Tambur A; Guo K; Zhao L; Levitsky J
Hum Immunol; 2021 Feb; 82(2):81-88. PubMed ID: 33213941
[TBL] [Abstract][Full Text] [Related]
7. Can the Toll-like receptors 4 expression in peripheral blood mononuclear cells help assess the effectiveness of immunosuppression and the chance of a future good renal transplant function?
Zmonarski SC; Madziarska K; Golebiowski T; Banasik M; Mazanowska O; Madziarski M; Krajewska M
Transpl Immunol; 2019 Apr; 53():43-50. PubMed ID: 30592973
[TBL] [Abstract][Full Text] [Related]
8. In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.
Eleftheriadis T; Pissas G; Sounidaki M; Antoniadi G; Antoniadis N; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2017 Sep; 49(9):1691-1697. PubMed ID: 28508247
[TBL] [Abstract][Full Text] [Related]
9. First UHPLC-MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients.
Pensi D; De Nicolò A; Pinon M; Pisciotta C; Calvo PL; Nonnato A; Romagnoli R; Tandoi F; Di Perri G; D'Avolio A
J Mass Spectrom; 2017 Mar; 52(3):187-195. PubMed ID: 28098395
[TBL] [Abstract][Full Text] [Related]
10. Intracellular tacrolimus concentration correlates with impaired renal function through regulation of the IS-AHR-ABC transporter in peripheral blood mononuclear cells.
Guo P; Zhang R; Zhou J; Li P; Liu Y; Shi S
Int Immunopharmacol; 2024 Jan; 126():111233. PubMed ID: 37979449
[TBL] [Abstract][Full Text] [Related]
11. Everolimus associated with low-dose calcineurin inhibitors, an option in kidney transplant recipients of very old donors.
Furian L; Silvestre C; Vallese L; Baldan N; Donato P; Bonfante L; Cavallin F; Marchini F; Rigotti P
Transplant Proc; 2014 Dec; 46(10):3390-5. PubMed ID: 25498057
[TBL] [Abstract][Full Text] [Related]
12. A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.
Robertsen I; Debord J; Åsberg A; Marquet P; Woillard JB
Clin Pharmacokinet; 2018 Nov; 57(11):1459-1469. PubMed ID: 29556934
[TBL] [Abstract][Full Text] [Related]
13. Effects of resveratrol on Th17 cell-related immune responses under tacrolimus-based immunosuppression.
Doh KC; Kim BM; Kim KW; Chung BH; Yang CW
BMC Complement Altern Med; 2019 Mar; 19(1):54. PubMed ID: 30832648
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
16. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
[TBL] [Abstract][Full Text] [Related]
17. Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations.
Robertsen I; Vethe NT; Midtvedt K; Falck P; Christensen H; Åsberg A
Ther Drug Monit; 2015 Oct; 37(5):675-80. PubMed ID: 25565673
[TBL] [Abstract][Full Text] [Related]
18. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
[TBL] [Abstract][Full Text] [Related]
19. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
20. Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Akamine Y; Habuchi T; Satoh S; Miura M
Int J Urol; 2016 Jun; 23(6):484-90. PubMed ID: 26990259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
